Monoamine oxidase A variant influences antidepressant treatment response in female patients with Major Depression.
The monoamine oxidase A (MAO-A) has been suggested to be involved in the pathogenesis as well as the pharmacological treatment of Major Depression. In the present study, 340 patients with a Major Depressive Episode (f=194, m=146; DSM-IV) of Caucasian descent were genotyped for the functional MAO-A VNTR. The clinical response to antidepressive pharmacological treatment was assessed by weekly intra-individual changes of HAM-D-21 scores over six weeks. The longer MAO-A alleles (3a, 4, 5) conferred a significant risk of slower and less efficient overall response over the course of 6 weeks of antidepressant treatment in patients with Major Depression, with the effect being restricted to female patients (p=0.028; corrected for multiple testing). The present results suggest that high-activity MAO-A genotypes possibly by consecutively decreased serotonin and/or norepinephrine availability negatively influence antidepressant treatment response during the first six weeks of pharmacological treatment in female patients with Major Depression.
Domschke
Katharina
K
Department of Psychiatry, University of Muenster, Albert-Schweitzer-Strasse 11, D-48143 Muenster, Germany. katharina.domschke@ukmuenster.de
Hohoff
Christa
C
Mortensen
Lena S
LS
Roehrs
Tilmann
T
Deckert
Jürgen
J
Arolt
Volker
V
Baune
Bernhard T
BT
D000328:Adult; D000483:Alleles; D000928:Antidepressive Agents / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000235:genetics*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018598:Minisatellite Repeats / Q000235:genetics*; D008995:Monoamine Oxidase / Q000235:genetics*; D010597:Pharmacogenetics; D011569:Psychiatric Status Rating Scales; D012189:Retrospective Studies; D012727:Sex Characteristics
D000928:Antidepressive Agents; D008995:Monoamine Oxidase